ArticleBiological psychiatry2018
Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer's Disease Dementia in Individuals With Mild Cognitive Impairment.
Article in Biological psychiatry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 2 syntheses or guidelines pooled it, 118 citations in OpenAlex.
- Can We UseCells · 2022Pooled it
- Long Non-coding RNA: Insight Into Mechanisms of Alzheimer's Disease.Frontiers in molecular neuroscience · 2021Pooled it
- Disturbed Spatial Learning and Hippocampal Molecular and Histological Alterations in Middle-Aged Rats with a History of Polycystic Ovary Syndrome.International journal of endocrinology and metabolism · 2027Article
- Elevated circulating BACE2 captures chronic glycemic burden and enhances the clinical identification of type 2 diabetes.iScience · 2026Article
- Age-dependent biphasic alterations and protein-activity decoupling of plasma BACE1 in major depressive disorder.Frontiers in psychiatry · 2026Article
- BACE-1 and ADAM-10 as Potential Peripheral Biomarkers for Alzheimer's Disease.Current pharmaceutical design · 2026Review
- Trofinetide Improves Cognitive Function in APP/PS1 Mice by Suppressing Inflammation and Apoptosis.Molecular neurobiology · 2025Article
- Late-onset alzheimer's disease, atherosclerosis, and cerebrovascular disease. A complex relationship too often neglected: a narrative review.Aging clinical and experimental research · 2025Review
- Insights into Biomarkers of Alzheimer's Disease: From Core Markers to Emerging Directions.Aging and disease · 2025Review
- Unveiling blood biomarkers for neuronal hyperplasticity: Insights from AD molecular subtyping, a comprehensive review.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Noninvasive Assessment of β-Secretase Activity Through Click Chemistry-Mediated Enrichment of Neuronal Extracellular Vesicles to Detect Alzheimer's Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Developing non-invasive molecular markers for early risk assessment of Alzheimer's disease.Biomarkers in neuropsychiatry · 2025Article
- Genetic and circulating biomarkers of cognitive dysfunction and dementia in CKD.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Review
- Elevated BACE1 and IFNγ+ T Cells in Patients with Cognitive Impairment and the 5xFAD Mouse Model.ACS chemical neuroscience · 2025Article
- Cognitive impairment in Sjogren's syndrome: Interplay between BACE1 activity, inflammatory blood biomarkers and neurocognitive testing.PloS one · 2025Article
- Article
- Developing Novel Beta-Secretase Inhibitors in a Computer Model as a Possible Treatment for Alzheimer's Disease.Advances in pharmacological and pharmaceutical sciences · 2025Article
- Blood-based biomarkers in mild behavioral impairment: an updated overview.Frontiers in neurology · 2025Review
- Increased PlasmaJournal of the American Heart Association · 2024Article
- Autoantibodies to BACE1 promote Aβ accumulation and neurodegeneration in Alzheimer's disease.Acta neuropathologica · 2024Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
16 authors at 10 institutions in 5 countries.
Funding
Abstract
backgroundIncreased beta-secretase 1 (BACE1) activity has consistently been detected in brain tissue and cerebrospinal fluid of subjects with mild cognitive impairment (MCI) and probable Alzheimer's disease (AD) compared with control subjects. The collection of cerebrospinal fluid by lumbar puncture is invasive. We sought to identify the presence of plasma BACE1 activity and determine potential alterations in subjects with MCI with clinical follow-up examinations for 3 years using patients with diagnosed probable AD dementia compared with healthy control subjects.
methodsSeventy-five patients with probable AD, 96 individuals with MCI, and 53 age-matched and sex-matched healthy control subjects were recruited from three independent international academic memory clinics and AD research expert centers. Plasma BACE1 activity was measured by a synthetic fluorescence substrate enzyme-linked immunosorbent assay. BACE1 protein expression was assessed by Western blotting using three different antibodies that recognize the epitopes of the N-terminus, C-terminus, and full-length BACE1.
resultsCompared with healthy control subjects, plasma BACE1 activity (V
conclusionsPlasma BACE1 activity is significantly increased in MCI converters and patients with probable AD. The sensitivities and specificities of BACE1 activity for the patients were 84% and 88%, respectively. Our results indicate that plasma BACE1 activity may be a biomarker for AD risk and could predict progression from prodromal to probable AD dementia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.